Logiscreen

Blueprint Medicines Corp

$0.00
Market Cap 8.27B
ROE -48.9%
Gross Margin 98.1%
Debt/Equity 2.1
Current Ratio 2.8
Revenue QoQ 55.5%
EPS QoQ -1.0%
F-Score 2

About

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-53.13
vs median 31.50
P/B
24.18
vs median 2.17
ROE
-0.49
vs median 0.09

Lower quality - review fundamentals carefully

Mid-cap company with growth potential

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics